Results 121 to 130 of about 2,682 (215)
British Journal of Pharmacology, EarlyView.Abstract Background and Purpose Doxorubicin (DOX) is a highly effective anthracycline, whose clinical application for cancer is limited by cardiotoxicity. The mechanisms underlying doxorubicin‐induced toxic cardiomyopathy (DICM) involve electrophysiological remodelling with intracellular Na+ overload because of increased late INa and hyperactivation of
Anna‐Lena Feder +7 more
wiley +1 more source
Heart failure medication to prevent cancer therapy–related cardiac dysfunction: A narrative review
British Journal of Pharmacology, EarlyView.Advances in oncological therapies have improved cancer survival but also have increased the clinical incidence of cancer therapy–related cardiac dysfunction (CTRCD), a spectrum of conditions ranging from subclinical biomarker or strain abnormalities to progressive heart failure and cardiogenic shock.
Fabian Voß +3 more
wiley +1 more source
Diabetic Medicine, EarlyView.Abstract Aims Coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), is more severe in people with diabetes mellitus due to immune dysfunction, exacerbated inflammation and increased risk of co‐morbidities and mortality.
Taís Mendes Camargo +4 more
wiley +1 more source
Diabetic Medicine, EarlyView.Abstract Background We compared characteristics of adults with insulin‐treated diabetes using continuous subcutaneous insulin infusion (CSII) versus multiple daily insulin injections (MDI) during admission with acute coronary syndrome (ACS) and identified factors associated with in‐hospital mortality among CSII users.
Harshal Deshmukh +6 more
wiley +1 more source
Diabetic Medicine, EarlyView.Abstract Aim To qualitatively explore adolescents with type 2 diabetes (T2D) using any treatment regimen and parents of such adolescents' experiences of a 6‐month trial of continuous glucose monitoring (CGM) and its perceived barriers and facilitators.
Maheesha Fernando +3 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims An update to the NICE Type 2 diabetes (T2DM) guideline in February 2022 recommended an SGLT2 inhibitor be offered to people with cardiovascular disease (CVD) or heart failure (HF) as comorbidities and considered for people at high CVD risk. We report uptake of this guideline in England 18 months after its publication.
Patrick Muller +12 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims Hypertension remains one of the most prevalent and consequential modifiable cardiovascular risk factors worldwide, affecting approximately 1.28 billion adults globally and nearly half of the United States population. Despite the availability of effective therapies, optimal blood pressure control is achieved in fewer than one in four ...
Matthew A. Cavender
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Endogenous hypercortisolism (EHC) is an underrecognised and clinically significant contributor to hypertension, particularly resistant hypertension. Once viewed as a rare entity, EHC is now understood as a spectrum of cortisol excess associated with adverse cardiometabolic outcomes and target‐organ damage.
Omar Al Dhaybi, Deepak L. Bhatt
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Background Individuals living with type 1 diabetes (T1D) are at increased risk for cardiovascular (CV) and renal complications, yet therapeutic strategies specifically targeting cardiorenal risk reduction in this population remain limited. The role of glucagon‐like peptide‐1 (GLP‐1)‐based therapies in T1D remains unclear.
Anastasios Tentolouris +5 more
wiley +1 more source
Diabetes, Obesity and Metabolism, EarlyView.ABSTRACT Aims To compare the efficacy and safety of insulin glargine 100 U/mL plus lixisenatide (iGlarLixi) with insulin degludec plus insulin aspart (IDegAsp) by baseline age, Type 2 diabetes (T2D) duration and glycated haemoglobin (HbA1c) in the Soli‐D study.
Saichun Zhang +14 more
wiley +1 more source